SHEN, Y. .; CHEN, X. .; ZHANG, H. .; HU, . H. Long-term cost-effectiveness analysis of onceweekly Semaglutide versus Dulaglutide for the treatment of type 2 diabetes after the renewal of the national drug reimbursement list in China. Health Decision, [S. l.], v. 2, n. S1, 2024. DOI: 10.54844/hd.2024.0003. Disponível em: https://www.hksmp.com/journals/hd/article/view/649. Acesso em: 2 may. 2025.